1
|
Cazzaniga ME, Ademuyiwa F, Petit T, Tio J, Generali D, Ciruelos EM, Califaretti N, Poirier B, Ardizzoia A, Hoenig A, Lex B, Mouret-Reynier MA, Giesecke D, Isambert N, Masetti R, Pitre L, Wrobel D, Augereau P, Milani M, Rask S, Solbach C, Pritzker L, Noubir S, Parissenti A, Trudeau ME. Low RNA disruption during neoadjuvant chemotherapy predicts pathologic complete response absence in patients with breast cancer. JNCI Cancer Spectr 2024; 8:pkad107. [PMID: 38113421 PMCID: PMC10765091 DOI: 10.1093/jncics/pkad107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2023] [Revised: 11/20/2023] [Accepted: 12/11/2023] [Indexed: 12/21/2023] Open
Abstract
In previously reported retrospective studies, high tumor RNA disruption during neoadjuvant chemotherapy predicted for post-treatment pathologic complete response (pCR) and improved disease-free survival at definitive surgery for primary early breast cancer. The BREVITY (Breast Cancer Response Evaluation for Individualized Therapy) prospective clinical trial (NCT03524430) seeks to validate these prior findings. Here we report training set (Phase I) findings, including determination of RNA disruption index (RDI) cut points for outcome prediction in the subsequent validation set (Phase II; 454 patients). In 80 patients of the training set, maximum tumor RDI values for biopsies obtained during neoadjuvant chemotherapy were significantly higher in pCR responders than in patients without pCR post-treatment (P = .008). Moreover, maximum tumor RDI values ≤3.7 during treatment predicted for a lack of pCR at surgery (negative predictive value = 93.3%). These findings support the prospect that on-treatment tumor RNA disruption assessments may effectively predict post-surgery outcome, possibly permitting treatment optimization.
Collapse
Affiliation(s)
- Marina Elena Cazzaniga
- Phase 1 Research Unit, IRCCS San Gerardo dei Tintori, Monza, MB, Italy
- School of Medicine and Surgery, Milano Bicocca University, Monza, MB, Italy
| | - Foluso Ademuyiwa
- Division of Medical Oncology, Washington University, Saint Louis, MO, USA
| | - Thierry Petit
- Institut Cancérologie Strasbourg Europe, Strasbourg, France
| | - Joke Tio
- Department of Gynecology and Obstetrics, Universitätsklinikum Münster, Münster, Germany
| | - Daniele Generali
- Breast Cancer Unit, ASST of Cremona and Department of Life Sciences, University of Trieste, Trieste, Italy
| | - Eva M Ciruelos
- Medical Oncology Department, Breast Cancer Unit, University Hospital, 12 de Octubre, Madrid, Spain
| | | | | | | | - Arnd Hoenig
- Breast Center, Women's Hospital, Marienhaus Hospital, Mainz, Germany
| | - Benno Lex
- Klinikum Kulmbach—Frauenheilkunde und Geburtshilfe, Kulmbach, Germany
| | | | - Dagmar Giesecke
- Hochtaunus-Kliniken Bad Homburg, Women’s Hospital, Bad Homburg, Germany
| | - Nicolas Isambert
- Pôle Régional de Cancérologie, Centre Hospitalier Universitaire de Poitiers, Poitiers, France
| | | | | | - Denise Wrobel
- Sozialstiftung Bamberg Klinikum Frauenklinik, Bamberg, Germany
| | | | - Manuela Milani
- Department of Gynecology and Obstetrics, Universitätsklinikum Münster, Münster, Germany
| | - Sara Rask
- Royal Victoria Regional Health Centre, Barrie, ON, Canada
| | - Christine Solbach
- Department of Gynecology and Obstetrics, University Hospital Frankfurt, Germany
| | | | | | - Amadeo Parissenti
- Policlinico Gemelli, Rome, Italy
- Rna Diagnostics, Inc, Toronto, ON, Canada
| | | |
Collapse
|
2
|
Butler P, Pascheto I, Lizzi M, St-Onge R, Lanner C, Guo B, Masilamani T, Pritzker LB, Kovala AT, Parissenti AM. RNA disruption is a widespread phenomenon associated with stress-induced cell death in tumour cells. Sci Rep 2023; 13:1711. [PMID: 36720913 PMCID: PMC9889758 DOI: 10.1038/s41598-023-28635-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2022] [Accepted: 01/23/2023] [Indexed: 02/01/2023] Open
Abstract
We have previously shown that neoadjuvant chemotherapy can induce the degradation of tumour ribosomal RNA (rRNA) in patients with advanced breast cancer, a phenomenon we termed "RNA disruption". Extensive tumour RNA disruption during chemotherapy was associated with a post-treatment pathological complete response and improved disease-free survival. The RNA disruption assay (RDA), which quantifies this phenomenon, is now being evaluated for its clinical utility in a large multinational clinical trial. However, it remains unclear if RNA disruption (i) is manifested across many tumour and non-tumour cell types, (ii) can occur in response to cell stress, and (iii) is associated with tumour cell death. In this study, we show that RNA disruption is induced by several mechanistically distinct chemotherapy agents and report that this phenomenon is observed in response to oxidative stress, endoplasmic reticulum (ER) stress, protein translation inhibition and nutrient/growth factor limitation. We further show that RNA disruption is dose- and time-dependent, and occurs in both tumourigenic and non-tumourigenic cell types. Northern blotting experiments suggest that the rRNA fragments generated during RNA disruption stem (at least in part) from the 28S rRNA. Moreover, we demonstrate that RNA disruption is reproducibly associated with three robust biomarkers of cell death: strongly reduced cell numbers, lost cell replicative capacity, and the generation of cells with a subG1 DNA content. Thus, our findings indicate that RNA disruption is a widespread phenomenon exhibited in mammalian cells under stress, and that high RNA disruption is associated with the onset of cell death.
Collapse
Affiliation(s)
- Phillipe Butler
- Graduate Program in Chemical Sciences, Laurentian University, Sudbury, ON, Canada
| | - Isabella Pascheto
- Graduate Program in Chemical Sciences, Laurentian University, Sudbury, ON, Canada
| | - Michayla Lizzi
- Graduate Program in Chemical Sciences, Laurentian University, Sudbury, ON, Canada
| | - Renée St-Onge
- Rna Diagnostics, Inc., Sudbury, ON, Canada.,Rna Diagnostics, Inc., Toronto, ON, Canada
| | - Carita Lanner
- Graduate Program in Chemical Sciences, Laurentian University, Sudbury, ON, Canada.,Division of Medical Sciences, Northern Ontario School of Medicine, Sudbury, ON, Canada
| | - Baoqing Guo
- Health Sciences North Research Institute, Sudbury, ON, Canada
| | - Twinkle Masilamani
- Rna Diagnostics, Inc., Sudbury, ON, Canada.,Rna Diagnostics, Inc., Toronto, ON, Canada
| | - Laura B Pritzker
- Rna Diagnostics, Inc., Sudbury, ON, Canada.,Rna Diagnostics, Inc., Toronto, ON, Canada
| | - A Thomas Kovala
- Graduate Program in Chemical Sciences, Laurentian University, Sudbury, ON, Canada.,Division of Medical Sciences, Northern Ontario School of Medicine, Sudbury, ON, Canada
| | - Amadeo M Parissenti
- Graduate Program in Chemical Sciences, Laurentian University, Sudbury, ON, Canada. .,Rna Diagnostics, Inc., Sudbury, ON, Canada. .,Rna Diagnostics, Inc., Toronto, ON, Canada. .,Health Sciences North Research Institute, Sudbury, ON, Canada. .,Division of Medical Sciences, Northern Ontario School of Medicine, Sudbury, ON, Canada.
| |
Collapse
|
3
|
Liquid biopsy based on small extracellular vesicles predicts chemotherapy response of canine multicentric lymphomas. Sci Rep 2020; 10:20371. [PMID: 33230132 PMCID: PMC7683601 DOI: 10.1038/s41598-020-77366-7] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2020] [Accepted: 11/04/2020] [Indexed: 12/11/2022] Open
Abstract
Lymphoma is the most common type of canine hematological malignancy where the multicentric (cMCL) form accounts for 75% of all cases. The standard treatment is the CHOP chemotherapy protocols that include cyclophosphamide, doxorubicin, vincristine and prednisone, where the majority of dogs achieve complete/partial response; however, it is very important to predict non-responsive cases to improve treatment and to develop new targeted therapies. Here we evaluate a liquid biopsy approach based on serum Small Extracellular Vesicles enriched for exosomes (SEVs) to predict cMCL chemotherapy response. Nineteen dogs at the end of the 19-week chemotherapy protocol (8 Complete Response and 11 Progressive Disease) were evaluated for serum SEVs size, concentration and screened for 95 oncomirs. PD patients had higher SEVs concentration at the diagnosis than CR patients (P = 0.034). The ROC curve was significant for SEVs concentration to predict the response to CHOP (AUC = 0.8011, P = 0.0287). A potential molecular signature based on oncomirs from SEVs (caf-miR-205, caf-miR-222, caf-mir-20a and caf-miR-93) is proposed. To the best of our knowledge, this is the first study demonstrating the potential of a liquid biopsy based on SEVs and their miRNAs content to predict the outcome of chemotherapy for canine multicentric lymphomas.
Collapse
|